ZVS203e

DRUG2 trials

Sponsors

Peking University Third Hospital, Chigenovo Co., Ltd

Conditions

Retinitis Pigmentosa

Early Phase 1

Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa

RecruitingNCT05805007

Peking University Third HospitalRetinitis Pigmentosa

Start: 2023-09-12End: 2026-04-30Target: 9Updated: 2023-10-24

Phase 1

Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation

RecruitingNCT06952842

Chigenovo Co., LtdRetinitis Pigmentosa

Start: 2025-08-04End: 2045-06-18Target: 18Updated: 2026-06-17

Related Papers

Systematic Identification of Candidate Genes for Inherited Retinal Disease Gene Therapy Integrating Worldwide IRD Cohort and Single-Cell Analysis.

2025-06-12